HK1002825A1 - Use of sertindole for the treatment of schizophrenia sertindole - Google Patents

Use of sertindole for the treatment of schizophrenia sertindole

Info

Publication number
HK1002825A1
HK1002825A1 HK98101302A HK98101302A HK1002825A1 HK 1002825 A1 HK1002825 A1 HK 1002825A1 HK 98101302 A HK98101302 A HK 98101302A HK 98101302 A HK98101302 A HK 98101302A HK 1002825 A1 HK1002825 A1 HK 1002825A1
Authority
HK
Hong Kong
Prior art keywords
sertindole
schizophrenia
treatment
dopamine neurones
neurones
Prior art date
Application number
HK98101302A
Other languages
English (en)
Inventor
Jens Kristian Perregaard
Torben Skarsfeldt
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10654774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1002825(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of HK1002825A1 publication Critical patent/HK1002825A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
HK98101302A 1989-04-11 1998-02-19 Use of sertindole for the treatment of schizophrenia sertindole HK1002825A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898908085A GB8908085D0 (en) 1989-04-11 1989-04-11 New therapeutic use

Publications (1)

Publication Number Publication Date
HK1002825A1 true HK1002825A1 (en) 1998-09-18

Family

ID=10654774

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98101302A HK1002825A1 (en) 1989-04-11 1998-02-19 Use of sertindole for the treatment of schizophrenia sertindole

Country Status (18)

Country Link
US (1) US5112838A (xx)
EP (1) EP0392959B1 (xx)
JP (1) JP2775191B2 (xx)
KR (1) KR920008703B1 (xx)
AT (1) ATE157005T1 (xx)
AU (1) AU621735B2 (xx)
CA (1) CA2014208C (xx)
CY (1) CY2082B1 (xx)
DE (2) DE19875011I2 (xx)
DK (1) DK0392959T3 (xx)
GB (1) GB8908085D0 (xx)
HK (1) HK1002825A1 (xx)
IE (1) IE81157B1 (xx)
IL (1) IL94021A (xx)
NL (1) NL980008I1 (xx)
NZ (2) NZ243765A (xx)
SG (1) SG48234A1 (xx)
ZA (1) ZA902785B (xx)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5238945A (en) * 1989-04-11 1993-08-24 H. Lundbeck A/S Method of treating psychoses
DK238190D0 (da) * 1990-10-03 1990-10-03 Lundbeck & Co As H Depotderivater
US5643784A (en) * 1990-12-04 1997-07-01 H, Lundbeck A/S Indan derivatives
NZ243065A (en) * 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions
DK206591D0 (da) * 1991-12-23 1991-12-23 Lundbeck & Co As H Behandling af psykoser
DK8492D0 (da) * 1992-01-23 1992-01-23 Lundbeck & Co As H Behandling af psykoser
DK123493D0 (da) * 1993-11-01 1993-11-01 Lundbeck & Co As H Compounds
WO1997035584A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Method for treating pain
ZA973433B (en) * 1996-04-24 1997-12-10 Shionogi & Co A sertindole-containing preparation and a method for producing the same.
CN1281335A (zh) * 1997-10-27 2001-01-24 科泰克斯药物股份有限公司 用安哌克和精神安定剂治疗精神分裂症
GB9805716D0 (en) * 1998-03-17 1998-05-13 Merck Sharp & Dohme Therapeutic agents
US6489341B1 (en) 1999-06-02 2002-12-03 Sepracor Inc. Methods for the treatment of neuroleptic and related disorders using sertindole derivatives
FR2802101B1 (fr) 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
US20040023951A1 (en) * 2001-06-18 2004-02-05 Bymaster Franklin Porter Combination therapy for treatment of psychoses
CA2468972A1 (en) * 2001-12-10 2003-07-03 Novartis Ag Methods of treating psychosis and schizophrenia based on a polymorphism in the cntf gene
IL163992A0 (en) * 2002-03-27 2005-12-18 Lundbeck & Co As H Method for manufacture of sertindole
BRPI0410271A (pt) * 2003-05-16 2006-05-16 Pfizer Prod Inc combinações terapêuticas de antipsicóticos atìpicos com moduladores de gaba, anticonvulsivantes ou benzodiazepinas
GB0326148D0 (en) 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
WO2005102366A2 (en) * 2004-04-19 2005-11-03 Philip Maxwell Satow Lithium combinations, and uses related thereto
WO2005107808A2 (en) * 2004-05-11 2005-11-17 Pfizer Products Inc. Combination of atypical antipsychotics and 5-ht1b receptor antagonists
AR049646A1 (es) * 2004-06-16 2006-08-23 Janssen Pharmaceutica Nv Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
TW200616608A (en) * 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
MX2007002309A (es) * 2004-08-24 2007-10-08 Johnson & Johnson Novedosos derivados de heteroarilsulfamida benzofusionados utiles como agentes anticonvulsivos.
CA2609185A1 (en) * 2005-05-20 2006-11-30 Ahmed F. Abdel-Magid Process for preparation of sulfamide derivatives
US20070212412A1 (en) * 2005-09-08 2007-09-13 H. Lundbeck A/S Stable solid formulation of sertindole
US8497298B2 (en) * 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US20070155824A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis
US8691867B2 (en) * 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
AR058389A1 (es) * 2005-12-19 2008-01-30 Janssen Pharmaceutica Nv Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
US20070191451A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives as neuroprotective agents
US20070191450A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Mania and Bipolar Disorder
US20070191460A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Disease Modification / Epileptogenesis
EP2026790A2 (en) * 2006-05-19 2009-02-25 Janssen Pharmaceutica, N.V. Co-therapy for the treatment of epilepsy and related disorders
TW200821296A (en) * 2006-06-01 2008-05-16 Lundbeck & Co As H Use of sertindole for the preventive treatment of suicidal behaviour
EP2041304B1 (en) 2006-06-12 2011-09-07 Hadasit Medical Research Services & Development Limited Rgs2 genotypes associated with extrapyramidal symptoms induced by antipsychotic medication
HUE032743T2 (en) 2006-11-22 2017-10-30 Clinical Res Ass Llc A method for treating Down syndrome, fragilis X syndrome and autism
WO2008106144A2 (en) * 2007-02-28 2008-09-04 Nupathe Inc. Implants for the treatment of psychiatric states
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
US20110034565A1 (en) 2008-04-18 2011-02-10 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
MX2011000090A (es) 2008-06-23 2011-03-02 Janssen Pharmaceutica Nv Forma cristalina de (2s)-(-)-n-(6-cloro-2,3-dihidro-benzo[1,4]diox in-2-ilmetil)sulfamida.
WO2009156889A1 (en) * 2008-06-25 2009-12-30 Pfizer Inc. Diaryl compounds and uses thereof
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
US8252801B1 (en) 2009-06-03 2012-08-28 Abbott Laboratories Treatment of schizophrenia and related disorders
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4359468A (en) * 1981-02-25 1982-11-16 Boehringer Ingelheim Ltd. Antiallergic N-[4-(indolyl)-piperidino-alkyl]-benzimidazolones
IE58370B1 (en) * 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
US4742057A (en) * 1985-12-05 1988-05-03 Fujisawa Pharmaceutical Co., Ltd. Antiallergic thiazole compounds
ZA891901B (en) * 1988-03-17 1989-11-29 Merrell Dow Pharma Method for the treatment of the extrapyramidal side effects associated with neuroleptic therapy

Also Published As

Publication number Publication date
AU621735B2 (en) 1992-03-19
EP0392959B1 (en) 1997-08-20
KR920008703B1 (ko) 1992-10-08
IL94021A0 (xx) 1991-01-31
KR900015730A (ko) 1990-11-10
GB8908085D0 (en) 1989-05-24
CY2082B1 (en) 1998-10-16
IE81157B1 (en) 2000-05-03
DE69031290D1 (de) 1997-09-25
JPH02290872A (ja) 1990-11-30
NZ233179A (en) 1996-12-20
CA2014208C (en) 1996-03-19
EP0392959A3 (en) 1992-05-06
DK0392959T3 (da) 1999-03-29
ZA902785B (en) 1991-06-26
AU5303790A (en) 1990-10-18
SG48234A1 (en) 1998-04-17
DE69031290T2 (de) 1998-01-02
IE901051L (en) 1990-10-11
NL980008I1 (nl) 1998-05-06
US5112838A (en) 1992-05-12
IL94021A (en) 1994-01-25
NZ243765A (en) 1997-09-22
ATE157005T1 (de) 1997-09-15
JP2775191B2 (ja) 1998-07-16
EP0392959A2 (en) 1990-10-17
DE19875011I2 (de) 2004-07-01
CA2014208A1 (en) 1990-10-11

Similar Documents

Publication Publication Date Title
SG48234A1 (en) Use of sertindole for the treatment of schizophrenia
TR200000129T2 (tr) Yepyeni spiroazabisiklik heterosiklik bileşikler.
DE69225421D1 (de) Sumatriptan enthaltende Arzneimittel
TW376319B (en) Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
DE69825292D1 (de) Verwendung von inosine zur herstellung eines medikamentes zur stimulierung des axonwachstums von zns-neuronen
SE8804629D0 (sv) New therapeutically active compounds
FI901357A0 (fi) Intraoralt medicingivarsystem.
NO178338C (no) Analogifremgangsmåte for fremstilling av en terapeutisk aktiv benzimidazolforbindelse samt mellomprodukt
ES2033879T3 (es) Derivados cetonicos como medicamentos para el tratamiento o prevencion del sindrome de abstinencia.
NO167204C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive diacylderivater av 4-(trialkylbenzyl)-piperazinylforbindelser.
YU242789A (en) New compound, 4-fluoro-2-//(4-metoxy-2-pyridin-yl)methylsulphinyl/-1h-benzimidazole and process for obtaining
NO167456C (no) Analogifremgangsmaate for fremstilling av den terapeutisk aktive forbindelse 7-(3-amino-1-pyrrolidinyl)-8-brom-1-syklopropyl-6-fluor-1,4-dihydro-4-okso-3-quinolinkarboksylsyre
AP9901474A0 (en) Pharmaceutical composition for treating viral diseases.
GR3004848T3 (xx)
MY133438A (en) Morpholinobenzamide salts
NO984651L (no) Anvendelse av benzonaftalenderivater for fremstilling av medikamenter for behandling av sykdommer i sentralnervesystemet
CA2154485A1 (en) Pharmaceutical composition containing 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone and its use for the treatment of cns disorders
JO1653B1 (en) The current benzimidazole is a therapeutically active method for preparing it
ES2150400A6 (es) Una composicion para el tratamiento de desordenes ulcerosos del tracto gastrointestinal.
IT8919216A0 (it) Dispositivo per la cura chirurgica dell'astigmatismo.
NO882279D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive endo-bicyklo (2,2,1) heptyl-adenosin-derivater.

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20100329